Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

G Van Assche; W J Sandborn; B G Feagan; B A Salzberg; D Silvers; P S Monroe; W M Pandak; F H Anderson; J F Valentine; G E Wild; D J Geenen; R Sprague; S R Targan; P Rutgeerts; V Vexler; D Young; R S Shames

doi:10.1136/gut.2005.089854

Article info

Inflammatory bowel disease

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Authors

G Van Assche Universitaire Ziekenhuizen Leuven, UZ Gasthuisberg, Leuven, Belgium PubMed articles Google scholar articles
W J Sandborn Mayo Clinic, Rochester, MN, USA PubMed articles Google scholar articles
B G Feagan Robarts Research Institute, University of Western Ontario, London, Ontario, Canada PubMed articles Google scholar articles
B A Salzberg Atlanta Gastroenterology Associates, Atlanta, GA, USA PubMed articles Google scholar articles
D Silvers Drug Research Services, Metairie, LA, USA PubMed articles Google scholar articles
P S Monroe Richmond GI Research Group, Richmond, VA, USA PubMed articles Google scholar articles
W M Pandak McGuire Department of Veterans Affairs Medical Center, Richmond, VA, USA PubMed articles Google scholar articles
F H Anderson Vancouver General Hospital, Vancouver, British Columbia, Canada PubMed articles Google scholar articles
J F Valentine Gainesville Veterans Administration Medical Center and University of Florida, Gainesville, FL, USA PubMed articles Google scholar articles
G E Wild McGill University Health Centre, Montreal, Quebec, Canada PubMed articles Google scholar articles
D J Geenen Wisconsin Center for Advanced Research, Milwaukee, WI, USA PubMed articles Google scholar articles
R Sprague Borland-Groover Clinic, Jacksonville, FL, USA PubMed articles Google scholar articles
S R Targan Cedars Sinai Medical Center, Los Angeles, CA, USA PubMed articles Google scholar articles
P Rutgeerts Universitaire Ziekenhuizen Leuven, UZ Gasthuisberg, Leuven, Belgium PubMed articles Google scholar articles
V Vexler PDL Biofarma, Fremont, California, USA, USA PubMed articles Google scholar articles
D Young PDL Biofarma, Fremont, California, USA, USA PubMed articles Google scholar articles
R S Shames PDL Biofarma, Fremont, California, USA, USA PubMed articles Google scholar articles

Correspondence to:
Dr G Van Assche
Universitaire Ziekenhuizen Leuven, Inwendige Geneeskunde, UZ Gasthuisberg, Herestraat 49-B–3000, Leuven, Belgium; gert.vanassche{at}uz.kuleuven.ac.be

View Full Text

Citation

Van Assche G, Sandborn WJ, Feagan BG, et al

Gut 2006;55:1568-1574.

Publication history

Revised March 7, 2006
Accepted March 14, 2006
First published April 7, 2006.

Online issue publication

January 10, 2022

Article Versions

Previous version (9 January 2022).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password